Search clinical trials for: BIBF 1120 capsules charge 1

Total 804 results

Boehringer Ingelheim

Completed

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Carcinoma, Non-Small-Cell Lung

Italy, Netherlands, Spain, United Kingdom
Temple University
Boehringer Ingelheim

Terminated

Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

Idiopathic Pulmonary Fibrosis | Lung Transplant; Complications

United States
Boehringer Ingelheim

Completed

Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects

Healthy
Martin-Luther-Universität Halle-Wittenberg
GALMED GmbH

Completed

TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) (AIO-KRK-0111)

Colorectal Cancer

Germany
M.D. Anderson Cancer Center
Boehringer Ingelheim

Terminated

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Breast Cancer

United States
Shanghai Chest Hospital

Not yet recruiting

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (CAMFA-L)

NSCLC

China
Boehringer Ingelheim

Completed

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Colorectal Neoplasms

United States, Argentina, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Taiwan, T... and more
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Healthy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7

United States
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF

Idiopathic Pulmonary Fibrosis

Japan
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States
Aktion Bronchialkarzinom e.V.
Boehringer Ingelheim

Completed

An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) (VENUS-1)

Carcinoma, Non-Small-Cell Lung

Germany
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Mónica Marazuela Azpíroz
Alba Garcimartín Álvarez; Carolina Knott Torcal; Nerea Aguirre Moreno; Miguel Antonio... and other collaborators

Completed

Phase II Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Spain
Boehringer Ingelheim

Completed

Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL in Healthy Adult Male Volunteers

Healthy
Aktion Bronchialkarzinom e.V.
Boehringer Ingelheim

Completed

An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) (VENUS-2)

Carcinoma, Non-Small-Cell Lung

Germany
Boehringer Ingelheim

Completed

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim

Completed

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Germany, China, Israel, Denmark, Belgium, Switzerland, Croatia, Poland, Romania, South Africa, Czechia, Greece, Portugal, United Kingdom, India, Italy, Austria, Belarus, Ukraine, Russian Federation, France, Bulgaria, Georgia, Korea... and more
Boehringer Ingelheim

Completed

A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim

Completed

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Genital Neoplasms, Female
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects

Healthy
Huahui Health

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers

COVID-19 Respiratory Infection

Australia
Nguyen Thi Trieu, MD

Completed

Composition for Treating Cirrhosis and Liver Cancer (SB-1121) (SB-1121)

Cirrhosis of the Liver

Vietnam
Boehringer Ingelheim

Completed

FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)

Prostate Hyperplasia
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Radicle Science

Completed

Radicle Health1: A Study of Health and Wellness Formulations and Their Effects on Overall Health

Depression | Pain | Sleep | Anxiety

United States
Boehringer Ingelheim

Completed

Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Vibrant Ltd.

Completed

Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers

Gastroparesis

United States
Northwestern University
University of Iowa; University of Rochester; Michael J. Fox Foundation for Parkinson...

Completed

Nilotinib in Parkinson's Disease (NILO-PD)

Parkinson Disease

United States
iN Therapeutics Co., Ltd.

Recruiting

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

Pain | Osteoarthritis | Chronic Pain | Neuropathic Pain | Post Herpetic Neuralgia

Australia
Beijing Ditan Hospital

Completed

A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

SARS-CoV-2 Infection

China
Boehringer Ingelheim

Completed

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Carcinoma, Renal Cell

United Kingdom, Poland, Hungary, Romania, Ukraine
Sinocelltech Ltd.

Not yet recruiting

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years

COVID-19 | SARS-CoV-2 Infection
Tehran University of Medical Sciences

Unknown

Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects

Obesity

Iran, Islamic Republic of
Boehringer Ingelheim

Completed

Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

Healthy
Melcap Systems Ltd.

Suspended

Safety and Feasibility Assessment of the Bio-electrical One Day Capsule System in Overweight and Class I Obese Participants

Overweight and Obesity

Israel
Arisan Therapeutics, Inc.
United States Department of Defense; Battelle Memorial Institute; The Defense...

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

Lassa Virus Infection

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

Heart Failure

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Heart Failure

United States
Beijing Continent Pharmaceutical Co, Ltd.

Completed

Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects

Hydronidone

China
Federal Budgetary Research Institution State Research...

Completed

Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects

Healthy
Hoosier Cancer Research Network
Boehringer Ingelheim

Terminated

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim

Completed

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

Lung Cancer | Lung Metastases

United States
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China

Search clinical trials for: BIBF 1120 capsules charge 1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations